Sally Adams
Directeur/Membre du Conseil chez Scancell Ltd.
Fortune : 8 792 $ au 30/04/2024
Profil
Sally Elizabeth Adams is currently a Director & Development Director at Scancell Ltd.
She previously worked as an Executive Director & Chief Development Officer at Scancell Holdings Plc, a Development Director at Neures Ltd., and Head-Neurology & Virology at Ligand UK Ltd.
Adams holds a doctorate from Imperial College London and a graduate degree from the University of Cambridge.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SCANCELL HOLDINGS PLC
0,01% | 19/12/2023 | 78 714 ( 0,01% ) | 8 792 $ | 30/04/2024 |
Postes actifs de Sally Adams
| Sociétés | Poste | Début |
|---|---|---|
Scancell Ltd.
 Scancell Ltd. Miscellaneous Commercial ServicesCommercial Services Scancell Ltd. researches and develops techniques for isolating foetal cells from a maternal blood sample. The company was founded by Lindy Durrant in 1997 and is headquartered in Nottingham, the United Kingdom. | Directeur/Membre du Conseil | - |
Anciens postes connus de Sally Adams
| Sociétés | Poste | Fin |
|---|---|---|
| SCANCELL HOLDINGS PLC | Directeur/Membre du Conseil | 05/02/2024 |
| VERNALIS | Corporate Officer/Principal | - |
| Neures Ltd. | Corporate Officer/Principal | - |
Formation de Sally Adams
| Imperial College London | Doctorate Degree |
| University of Cambridge | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SCANCELL HOLDINGS PLC | Health Technology |
| Entreprise privées | 3 |
|---|---|
Ligand UK Ltd.
 Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
Scancell Ltd.
Scancell Ltd. Miscellaneous Commercial ServicesCommercial Services Scancell Ltd. researches and develops techniques for isolating foetal cells from a maternal blood sample. The company was founded by Lindy Durrant in 1997 and is headquartered in Nottingham, the United Kingdom. | Commercial Services |
| Neures Ltd. |